Dexcom has unveiled its innovative generative AI (GenAI) platform, marking the first integration of GenAI in glucose biosensing technology. The platform utilizes Google Cloud’s Vertex AI and Gemini models to deliver actionable, personalized insights to users.

The GenAI technology initially enhances Stelo’s Weekly Insights feature, providing tailored tips and recommendations on diet, exercise, and sleep. Stelo, Dexcom's FDA-cleared over-the-counter glucose biosensor, aims to empower users to better understand and manage metabolic health.

Jake Leach, Dexcom’s Chief Operating Officer, emphasized the innovation's significance: “This launch reinforces our long-standing leadership in glucose biosensing and paves the way for additional GenAI-powered features to help users make proactive, informed lifestyle decisions.”

Dexcom plans to expand GenAI capabilities across its product portfolio in the coming year, continuing to transform glucose monitoring and health management.

For more information, please visit Fierce Biotech.